Piramal Pharma Solutions expands in-vitro biology capabilities at Ahmedabad Discovery Services Site

The benefits of this new investment will be seen in an improved experience for PPS discovery services customers

Piramal Pharma Solutions (PPS) business today announced that the company has made a multi-million dollar investment to create a world-class high-throughput screening facility that will augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site, a statement from Piramal Pharma Solutions said.

The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. With integrated chemistry and biology services now available from a single site, we anticipate significant improvements to drug discovery cycle times. In addition, new personnel with experience in biology services are being added to the site team, complementing the existing technical and operational expertise, the statement added.

It also added that the new high-throughput screening technology enables PPS to evaluate and screen 1,000 compounds per week using various assay platform technologies such as Fluorescent Imaging Plate Reader (FLIPR), TR-FRET/HTRF, Fluorescence Polarisation (FP), absorbance, Luminescence/ Electrochemiluminescence (ECL), Alpha Screen, Lantha Screen, Flow Cytometry and high content imaging. These platforms will be applicable to a variety of targets (e.g., G-protein-coupled receptors (GPCRs) and kinase-targeted therapies).

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said, “Assisting customers in the discovery process is synergistic with our efforts to be a patient-centric CDMO. With this investment, we are enhancing our discovery platform by adding new in-vitro biology services to our existing capabilities, making us a more integrated partner.”

CDMOin-vitro biology capabilitiesPiramal Pharma Solutions
Comments (0)
Add Comment